ABSTRACT
Objective To investigate the effect of Tegafur, Gimeracil and Oteracil Potassium Capsules ( TS-1 ) on peripheral blood tissue polypeptide antigen (TPS), soluble MHC class I chain-related molecules A (sMICA), hypoxia-inducible factor-1 (HIF-1α) and human epidermal growth factor receptor 2 ( Her-2 ) in the treatment of patients with advanced cervical cancer.Methods 80 cases with advanced cervical cancer were selected and divided into two groups, 40 cases in the control group were treated with routine clinical therapy, 40 cases in the experimental group were treated with TS-1.Tumor markers, TPS,sMICA,HIF-1αand Her-2 were compared before and after the treatment.Results Compared with the control group, the levels of tumor antigen TA-4,carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCCA) in the experimental group were lower (P<0.05); the TPS, HIF-1, sMICA and Her-2 were lower (P<0.05), and the total effective rate in the treatment group was higher (P<0.05).Conclusion TS-1 has a obvious clinical efficacy in the treatment of advanced cervical cancer.It is speculated that the possible mechanism may reduce the serum tumor marker levels via reducing the TPS and SMICA, HIF-1 alpha, HER-2 levels.
ABSTRACT
Objective To evaluate the clinical diagnostic application and operative efficacy of the expression of NKG2D in peripheral blood CD+8 NKT cell and its ligand sMICA in patients with esophageal or cardiac carcinoma.Methods The peripheral blood NKG2D positive CD+8 NKT cell percentage was concomitantly determined by flow cytometry in 53 preoperative patients including 29 postoperative patients with esophageal or cardiac carcinoma and 30 healthy controls.The serum sMICA was determined by ELISA.Results The peripheral blood NKG2D positive CD+8 NKT cell percentage in patients was significantly lower than that in controls [(77.632±8.972) % vs (89.053±6.515) %] (t = -6.113,P ＜0.05); with stage Ⅱ,Ⅲ,Ⅳ,it decreased significantly in order (F = 99.251,P ＜0.01);with lymph node metastasis lower than that without lymph node metastasis (t = -10.384,P ＜0.01); squamous carcinoma was higher than adenocarcinoma (t =9.899,P ＜0.01); postoperative was significantly higher than preoperative (t =-4.319,P ＜0.01).The level of serum sMICA in patients was significantly higher than that in controls [(326.28±85.407) pg/ml vs (210.00±92.560) pg/ml](t =7.292,P ＜0.01); with stage Ⅱ,Ⅲ,Ⅳ,it increased significautly in order (F =63.355,P ＜0.01); with lymph node metastasis higher than that without lymph node metastasis (t =7.770,P ＜0.01); squamous carcinoma was lower than adenocarcinoma (t =-7.593,P＜0.01); postoperative was significantly lower than preoperative (t =7.027,P ＜0.01).Serum sMICA could inhibit peripheral blood CD+8 NKT cell activation receptor NKG2D (F =142.773,P ＜0.05),determination coefficient R2 = 0.7368.Conclusion The level of peripheral blood CD+8NKT cell activation receptor NKG2D and serum sMICA in patients could be an assistant indicator for
ABSTRACT
Objective To evaluate the diagnosis and the clinical application value of serum soluble MICA protein in patients with esophageal carcinoma or cardiac carcinoma.Methods The serum sMICA was concomitantly determined by ELISA in 50 preoperative patients with esophageal carcinoma or cardiac carcinoma and 20 healthy controls.Results The level of serum sMICA in patients was significantly higher than that in controls[(322.42±9.09)pg/ml,(176.00±11.69)pg/ml](P＜0.01).In patients with TNM stage Ⅱ,Ⅲ,Ⅳ,the level of serum sMICA increased significantly in order(P＜0.05).In patients with lymph node metastasis.the level of serum sMICA was significantly higher than that without lymph node metastasis.The level of serum sMICA in patients with imbricate carcinoma was higher than patients with glandiform carcinoma.In patients with TNM stageⅢ.the level of serum sMICA after operation was significantly lower than that before operation.ConclusionSerum sMICA could be an assistant indicator for esophageal carcinoma or cardiac carcinoma.sMICA could be considered as a new tumour symbol to evaluate the biological behavior and prognosis of esophageal and cardiac carcinoma.